Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Risk factors for de novo hepatitis B during solid cancer treatment
Rie Sugimoto, Masayuki Furukawa, Takeshi Senju, Yoshihusa Aratake, Mototsugu Shimokawa, Yuki Tanaka, Hiroki Inada, Tatsuya Noguchi, Lingaku Lee, Masami Miki, Yuji Maruyama, Risa Hashimoto, Terumasa Hisano
Rie Sugimoto, Masayuki Furukawa, Takeshi Senju, Yoshihusa Aratake, Yuki Tanaka, Hiroki Inada, Tatsuya Noguchi, Lingaku Lee, Masami Miki, Yuji Maruyama, Risa Hashimoto, Terumasa Hisano, Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, Fukuoka City 811-1395, Fukuoka Prefecture, Japan
Mototsugu Shimokawa, National Hospital Organization Kyushu Cancer Center, Clinical Research Institute, Fukuoka City 811-1395, Fukuoka Prefecture, Japan
Mototsugu Shimokawa, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube City 755-8505, Yamaguchi Prefecture, Japan
Author contributions: Sugimoto R designed the study, collected and analyzed the data, and drafted the first manuscript; Furukawa M prepared and reviewed the manuscript; Senju T and Aratake Y collected and analyzed the data; Shimokawa M analyzed and reviewed the data; Tanaka Y, Inada H and Noguchi T collected the data; Lee L and Miki M participated in the acquisition and interpretation of the data; Maruyama Y prepared and reviewed the manuscript; Hashimoto R and Hisano T analyzed the data.
Supported by Eisai Corporation, No. HHCS20181030011.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the National Hospital Organization Kyushu Cancer Center (Approval No.2017-16).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to participate in clinical research by written consent. For full disclosure, the details of the study are published on the home page of National Hospital Organization Kyushu Cancer Center and patients are asked to inform us if they disagree with the use of the clinical data.
Conflict-of-interest statement: This work was partly supported by funding from Eisai (Grant No. HHCS20181030011) (Tokyo, Japan); however, that did not result in potential conflicts for this study because it was designed and performed independently of this funding agency.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at sugirie5@yahoo.co.jp. Participants gave informed consent for data sharing.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
http://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Rie Sugimoto, MD, PhD, Chief Doctor, Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, 3-1-1 Notame Minami-ku, Fukuoka City 811-1395, Fukuoka Prefecture, Japan. sugirie5@yahoo.co.jp
Received: August 31, 2020
Peer-review started: August 31, 2020
First decision: September 30, 2020
Revised: October 13, 2020
Accepted: November 2, 2020
Article in press: November 2, 2020
Published online: December 26, 2020
